West Pharmaceutical stock heads into the open after a 0.7 percent dip

West Pharmaceutical stock closed at USD 338.79 on the New York Stock Exchange on September 9, 2026, down 0.7% from the prior session. Per broad market data, the major US equity indexes also ended lower that day, so the shares moved broadly in line with the overall market environment.

September 9, 2026 in numbers

West Pharmaceutical Services Inc. (ISIN US9523901012, NYSE: WST) ended the September 9, 2026 session at USD 338.79 after trading between an intraday high of roughly USD 340 and a low in the mid-330s, according to New York Stock Exchange quote data. Trading volume reached 23,467 shares, which was well below the company’s recent average daily volume of 840,700 shares, indicating a relatively quiet session in terms of turnover, as noted by MarketBeat data. The stock’s recent 52 week range runs from USD 223.83 to USD 386.00, placing the latest close closer to the upper end of that band than to the low, according to MarketBeat. In the broader market, US large cap benchmarks such as the S&P 500 also finished the September 9, 2026 session in negative territory, underscoring that the move in West Pharmaceutical occurred against a backdrop of risk-off sentiment across equities.

From a positioning perspective, institutional investors remain the dominant owners of West Pharmaceutical, with more than 90% of the float held by institutions, according to MarketBeat. MarketBeat also reported that asset manager Amundi recently reduced its holdings in the company, a move that fits into an active institutional rebalancing around the stock.

Today’s catalysts for West Pharmaceutical

Looking ahead to today’s session, the most recent company specific development is new analyst coverage from UBS Group. As MarketBeat reported on September 9, 2026, UBS initiated coverage of West Pharmaceutical with a buy rating and set a price target of USD 415, adding a fresh positive analyst view to the name that investors may weigh as trading resumes today. In addition, UBS’s stance follows recent commentary that highlighted West Pharmaceutical’s second quarter 2026 performance, where adjusted earnings per share of USD 2.37 and revenues of USD 872.3 million topped consensus estimates, according to Yahoo Finance. On the macro side, US index futures point to a mixed open for equities ahead of key inflation data releases, a backdrop that could influence trading in health care and medical supply names such as West Pharmaceutical as investors reassess interest rate expectations, according to Yahoo Finance. No specific corporate events for West Pharmaceutical are scheduled for today in the public calendars used here, so market participants are likely to focus on the new UBS coverage, the stock’s relative valuation versus its recent range, and the broader reaction to the latest US economic data as the New York session gets under way.